Second, some KRAS mutations are immunogenic and can elicit endogenous anti-KRAS T cell responses (5–8), and T cells targeting tumor neoantigens appear to be the main mediators of many effective cancer immunotherapies in humans (9). The gene discussed is KRAS; the disease is neoplasm.